title: Using Hawthorne effects to improve adherence in clinical practice: lessons from clinical trials--reply.
authors.forename: Joel M
authors.initials: JM
authors.lastname: Gelfand
authors.forename: Shuwei
authors.initials: S
authors.lastname: Wang
authors.forename: Junko
authors.initials: J
authors.lastname: Takeshita
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Robertson
authors.forename: Gerald G
authors.initials: GG
authors.lastname: Krueger
authors.forename: Kristina
authors.initials: K
authors.lastname: Callis Duffin
authors.forename: Abby S
authors.initials: AS
authors.lastname: Van Voorhees
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D011565:Psoriasis / Q000628:therapy*; D014467:Ultraviolet Therapy
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D008727:Methotrexate